[1]杨少宁 曾晓荣 于小勇.中西医防治血液透析高血压的研究进展[J].现代中医药,2020,(04):102-107.[doi:10.13424/j.cnki.mtcm.2020.04.026]
 Yang Shaoning,Zeng Xiaorong,Yu Xiaoyong.Research Progress on the Prevention and Treatment of Hemodialysis Hypertension by the Combination of the Western and Chinese Medicine[J].Modern Traditional Chinese Medicine,2020,(04):102-107.[doi:10.13424/j.cnki.mtcm.2020.04.026]
点击复制

中西医防治血液透析高血压的研究进展()
分享到:

《现代中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2020年04期
页码:
102-107
栏目:
出版日期:
2020-07-10

文章信息/Info

Title:
Research Progress on the Prevention and Treatment of Hemodialysis Hypertension by the Combination of the Western and Chinese Medicine
文章编号:
1672-0571(2020)04-0102-06
作者:
杨少宁1 曾晓荣2 于小勇2
1.陕西中医药大学,陕西 咸阳 712046;
2.陕西省中医医院,陕西 西安 710003
Author(s):
Yang Shaoning 1 Zeng Xiaorong 2 Yu Xiaoyong 2
1. Shaanxi University of Chinese Medicine, Xianyang Shaanxi 712046
2. Shaanxi Hospital of Traditional Chinese Medicine, Xi’ an Shaanxi 710003
关键词:
血液透析高血压机制中西医防治措施综述
Keywords:
Hemodialysis Hypertension mechanism the Western and Chinese Medicine the prevention and treatment strategy a review
分类号:
R259
DOI:
10.13424/j.cnki.mtcm.2020.04.026
文献标志码:
A
摘要:
血液透析高血压是指部分血液透析患者,在血液透析前后的血压升高,通常不容易被控制,并伴有许多不良后果。这一现象多年来一直困扰着临床医生,因为它偏离了预期的透析结果,其血压并没有随着透析超滤的增加而得到明显改善。与其他血液透析患者相比,此类患者的年龄更大,合并症更多,并且具有显著的细胞外容量超负荷以及透析时间较短的特点。因此最近已经被确定为一个独立的死亡风险因素。结合文献,从血液透析高血压的定义、机制、中西医防治措施等方面,将近年来有关血液透析高血压的研究进行综述,以探讨其临床应用价值。
Abstract:
Hemodialysis Hypertension refers to the elevation of blood pressure before and after the hematodialysis occurring to part of the patients. It is not easy to control this disease and many side effects are accompanying subsequently.The clinical physicians are obsessed with this phenomenon for a long time because it deviates from the expectant dialysis result and the blood pressure has not been apparently improved along with the increase of the dialysis ultrafiltration. In contrast with the other patients, these older ones have more complications and the characteristics of the significant extracellular volume overload and short - term dialysis. Thus this disease has been identified as a unique risk factor causing death. This paper makes a review of the recent literature on the Hemodialysis Hypertension in terms of its definition,mechanism, the prevention and treatment strategy from the Western and Chinese Medicine. to explore it’ s value in clinical application.

参考文献/References:

[1] Van Buren P N. Pathophysiology and implications of intradialytic hypertension[ J] . Curr Opin Nephrol Hypertens,2017,26( 4) :303 -310.
[2] Van Buren P N, Inrig J K. Special situations: Intradialytic hypertension/ chronic hypertension and intradialytic hypotension[ J] . Semin Dial, 2017,30( 6) :545 -552.
[3] Georgianos P I, Agarwal R. Meet the twins: intradialyticand interdialytic hypertension[ J] . Am J Nephrol, 2018,48( 4) :292 -294.
[4] Van Buren P N, Inrig J K. Mechanisms and treatment of intradialytic hypertension[ J] . Blood Purif, 2016, 41( 1/3) :188 -193.
[5] Van Buren P N, Zhou Y, Neyra J A, et al. Extracellular volume overload and increased vasoconstriction in patients with recurrent intradialytic hypertension[ J] . Kidney Blood Press Res, 2016,41( 6) :802 -814.
[6] Sarafidis P A, Persu A, Agarwal R, et al. Hypertension in dialysis patients: a consensus document by the European renal and cardiovascular medicine ( EURECA - m) working group of the european renal association - european dialysis and transplant association ( ERA - EDTA) and the hypertension and the kidney working group of the European society of hypertension ( ESH) [ J] . Nephrol Dial Transplant, 2017,32( 4) :620 -640.
[7] Dahlmann A, D? rfelt K, Eicher F, et al. Magnetic resonance - determined sodium removal from tissue stores in hemodialysis patients[ J] . Kidney Int, 2015, 87( 2) : 434-441.
[8] Ren H, Gong D, He X, et al. Evaluation of intradialytic hypertension using bioelectrical impedance combined with echocardiography in maintenance hemodialysis patients [ J] . Ther Apher Dial, 2018,22( 1) :22 -30.
[9] Georgianos P I, Mpoutsiouki F, Sabani E, et al. Hemodialysis patients with intradialytic rise in blood pressure display higher baseline aortic stiffness and negligible drop in augmentation index with dialysis[ J] . Int Urol Nephrol,2016,48( 4) :601 -608.
[10] Georgianos P I, Sarafidis P A, Lasaridis A N. Arterial stiffness: a novel cardiovascular risk factor in kidney disease patients[ J] . Curr Vasc Pharmacol, 2015, 13( 2) :229 -238.
[11] Papademetriou V, Doumas M, Anyfanti P, et al. Renal nerve ablation for hypertensive patients with chronic kidney disease[ J] . Curr Vasc Pharmacol, 2014,12( 1) :47 -54.
[12] Raptis V, Kapoulas S, Grekas D. Role of asymmetrical dimethylarginine in the progression of renal disease[ J] . Nephrology ( Carlton) , 2013,18( 1) :11 -21.
[13] Teng J, Tian J, Lv W L, et al. Inappropriately elevated endothelin -1 plays a role in the pathogenesis of intradialytic hypertension[ J] . Hemodial Int, 2015,19( 2) :279 -286.
[14] Boyle S M, Berns J S. Erythropoietin and resistant hypertension in CKD[ J] . Semin Nephrol, 2014,34( 5) :540-549.
[15] Del V L, Locatelli F. An overview on safety issues related to erythropoiesis - stimulating agents for the treatment of anaemia in patients with chronic kidney disease[ J] .Expert Opin Drug Saf, 2016,15( 8) :1021 -1030.
[16] Tada T, Kusano K F, Ogawa A, et al. The predictors of central and obstructive sleep apnoea in haemodialysis patients[ J] . Nephrol Dial Transplant, 2007,22( 4) :1190 -1197.
[17] Ogna A, Forni O V, Mihalache A, et al. Obstructive sleep apnea severity and overnight body fluid shift before and after hemodialysis[ J] . Clin J Am Soc Nephrol, 2015, 10( 6) :1002 -1010.
[18] Abdel - Kader K, Dohar S, Shah N, et al. Resistant hypertension and obstructive sleep apnea in the setting of kidney disease [ J] . J Hypertens, 2012, 30 ( 5) : 960-966.
[19] Chen J, Gul A, Sarnak M J. Management of intradialytic hypertension: the ongoing challenge [ J] . Semin Dial, 2006,19( 2) :141 -145.
[20] Assimon M M, Wang L, Flythe J E. Intradialytic hypertension frequency and short - term clinical outcomes among individuals receiving maintenance hemodialysis[ J] . Am J Hypertens, 2018,31( 3) :329 -339.
[21] Inrig J K, Van Buren P, Kim C, et al. Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction [ J] . Clin J Am Soc Nephrol, 2012,7( 8) :1300 -1309.
[22] Pullalarevu R, Akbar G, Teehan G. Secondary hypertension, issues in diagnosis and treatment[ J] . Prim Care, 2014,41( 4) :749 -764.
[23] Wolfmueller Z, Goyal K, Prasad B. Bilateral renal artery stenosis as a cause of refractory intradialytic hypertension in a patient with end stage renal disease[ J] . BMC Nephrol, 2019,20( 1) :19.
[24] Raikou V D, Kyriaki D. The association between intradialytic hypertension and metabolic disorders in end stage renal disease[ J] . Int J Hypertens, 2018,2018:1681056.
[25] Inrig J K. Intradialytic hypertension: a less – recognized cardiovascular complication of hemodialysis [ J] . Am J Kidney Dis, 2010,55( 3) :580 -589.
[26] Hompesch C, Ma T, Neyra J A, et al. Comparison of ambulatory blood pressure patterns in patients with intradialytic hypertension and hemodialysis controls[ J] . Kidney Blood Press Res, 2016,41( 3) :240 -249.
[27] Agarwal R, Alborzi P, Satyan S, et al. Dry - weight reduction in hypertensive hemodialysis patients ( DRIP) : a randomized controlled trial[ J] . Hypertension, 2009, 53 ( 3) :500 -507.
[28] Zhu F, Rosales L, Kotanko P. Techniques for assessing fluids status in patients with kidney disease[ J] . Curr Opin Nephrol Hypertens, 2016,25( 6) :473 -479.
[29] Inrig J K, Molina C, D'Silva K, et al. Effect of low versus high dialysate sodium concentration on blood pressure and endothelial - derived vasoregulators during hemodialysis: a randomized crossover study[ J] . Am J Kidney Dis,2015,65( 3) :464 -473.
[30] Kotanko P, Garg A X, Depner T, et al. Effects of frequent hemodialysis on blood pressure: Results from the randomized frequent hemodialysis network trials[ J] . Hemodial Int, 2015,19( 3) :386 -401.
[31]刘红勇,李少敏,叶玉球,等.透析患者高血压病研究现状[J].新医学,2018,49(08):546-550.
[32] Bikos A, Loutradis C, Angeloudi E, et al. The effects of nebivolol and irbesartan on postdialysis and ambulatory blood pressure in patients with intradialytic hypertension: a randomized cross - over study[ J] . J Hypertens, 2019, 37( 2) :432 -442.
[33] Morganti A, Mancia G. Resistant hypertension: renal denervation or intensified medical treatment? [ J] . Eur J Intern Med, 2018,50:6 -11.
[34] Knehtl M, Bevc S, Hojs R, et al. Bilateral nephrectomy for uncontrolled hypertension in hemodialysis patient: a forgotten option? [ J] . Nephrol Ther, 2014, 10( 7) : 528-531.
[35] Lobo M D, Sobotka P A, Stanton A, et al. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension ( the ROX CONTROL HTN study) : a randomised controlled trial[ J] . Lancet, 2015, 385 ( 9978) :1634 -1641.
[36] Hikita H, Kojima K, Kimura S, et al. Impact of renal artery stent implantation on hypertension in patients with hemodialysis[ J] . Int J Angiol, 2014,23( 2) :107 -110.
[37]杨简,陈星华,丁国华.维持性血液透析高血压及其治疗进展[J].中国全科医学,2017,20(6):755-758.
[38] Li J, Sun M, Ye J, et al. The mechanism of acupuncture in treating essential hypertension: a narrative review[ J] .DOI:10. 1155/2019/8676490.
[39]于思明,苑芳.针灸治疗血液透析合并高血压疗效观察[J].山西中医,2016,32(3):30-32.
[40]李亚清.针刺配合穴位外敷对血液透析并高血压的影响[J].江西中医学院学报,2006,18(4):36-37.
[41]麦建玲,郭小卫.平衡针治疗血液透析高血压的临床护理观察[J].现代中西医结合杂志,2011,20(29):3741-3742.
[42]林书洲.平衡针灸治疗血液透析过程中高血压的短期临床疗效观察[D].广州:广州中医药大学,2010.
[43]李康.针刺人迎穴治疗尿毒症患者透析相关高血压验案三则[J].中医临床研究,2018,10(01):34-35.
[44]高志霞,李华珍.耳穴贴压联合中医综合干预对糖尿病肾病血液透析患者高血压的影响[J].中国民间疗法,2019,27(06):19-20.
[45]张飞飞.耳穴贴压和中医护理对糖尿病肾病血液透析患者高血压的影响评价[J].实用临床护理学电子杂志,2018,3(39):118-120.
[46]史鲜利.耳穴贴压对维持性血液透析43例血压及睡眠质量的影响[J].中国民族民间医药,2018,27(19):104-105.
[47]刘洁.耳穴贴压配合中医护理对糖尿病肾病血液透析高血压的影响[J].内蒙古中医药,2017,36(14):98.
[48]陈永美,纪宇,高玉娇.耳穴贴压配合中医护理对糖尿病肾病血液透析患者高血压的影响[J].中外女性健康研究,2018,(6):75-140.
[49]艾松园.耳穴贴压配合中医护理对糖尿病肾病血液透析患者高血压的影响[J].中西医结合心血管病电子杂志,2014,2(9):135-136.
[50]华琼,关明智.中西医结合治疗尿毒症患者难治性高血压42例[J].中医研究,2010,23(11):46-47.
[51]王婧.地黄汤加减联合血液透析治疗尿毒症难治性高血压的效果探析[J].当代医药论丛,2017,15(24):177-178.
[52]徐梅昌.中西医结合防治透析患者高血压30例[J].中国中医药现代远程教育,2011,9(23):127-128.
[53]张作臻.吴茱萸穴位贴敷治疗血液透析过程中高血压的临床观察[D].济南:山东中医药大学,2016.

相似文献/References:

[1]王 丹.中西医药治疗脾虚气滞证功能性消化不良的机制研究[J].现代中医药,2019,(05):111.[doi:10.13424/j.cnki.mtcm.2019.05.033]
[2]李军义1 罗振强2.小针刀配合手法治疗颈性眩晕45例疗效观察[J].现代中医药,2019,(04):037.[doi:10.13424/j.cnki.mtcm.2019.04.011]
[3]万敏1,2 刘繁荣2.扶正化瘀胶囊治疗乙肝病毒肝硬化代偿期 40 例[J].现代中医药,2019,(02):080.[doi:10.13424/j.cnki.mtcm.2019.02.025]
[4]宋娜吴施国谢星星邱祥玉汤小虎.中药干预肝癌及其疼痛的分子机制研究进展[J].现代中医药,2021,(04):001.[doi:10.13424/j.cnki.mtcm.2021.04.001]
 SONG Na WU Shiguo XIE Xingxing QIU Xiangyu TANG Xiaohu.Research Progress on Molecular Mechanism of TraditionalChinese Medicine Intervention on Liver Cancer and Its Pain[J].Modern Traditional Chinese Medicine,2021,(04):001.[doi:10.13424/j.cnki.mtcm.2021.04.001]
[5]林瑞磷阮传亮苏稼夫徐榕壑曾萍萍陈晓彤.脊髓损伤后勃起功能障碍的临床研究进展[J].现代中医药,2024,(02):014.[doi:10.13424/j.cnki.mtcm.2024.02.003]
[6]殷苗苗睢建亮王梦蕾刘会云刘齐超一峰王珍.摩罗丹浓缩丸治疗慢性萎缩性胃炎的药效及作用机制[J].现代中医药,2024,(02):098.[doi:10.13424/j.cnki.mtcm.2024.02.018]
 YIN MiaomiaoSUI JianliangWANG MengleiLIU HuiyunLIU QichaoWU YifengWANG Zhen.Morodan Concentrated Pills for the Treatment of Chronic Atrophic Gastritis and Its Mechanism of Action[J].Modern Traditional Chinese Medicine,2024,(04):098.[doi:10.13424/j.cnki.mtcm.2024.02.018]

备注/Memo

备注/Memo:
基金项目:陕西省重点研发计划项目(2017SF-298)
通讯作者:于小勇,硕士研究生导师,主任医师?E-mail:218020621271@email.sntcm.cn
更新日期/Last Update: 2020-07-15